Pfizer, a New York-based pharmaceuticals firm, sold 640 million Haleon shares at 380 pence per share in a placing run by Goldman Sachs International and BofA Securities as joint global coordinators.

Pfizer has sold a stake in British consumer healthcare group Haleon worth about $3.26 billion, cutting its shareholding in ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

In our latest podcast episode, we speak to former Royal Marine Mark Ormrod who opens up about resilience and how he stays ...

Investment bank Peel Hunt today said market activity has slowed in recent weeks ahead of the upcoming Budget and US ...

Greggs has indicated an easing of cost inflation as it made "further good progress" in the third quarter. Plus, the BRC ...

The Australian pilots union said on Tuesday that it has rejected a wage proposal from Qantas Airways for its short haul ...

(Reuters) - Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in ...

From US drugmaker Pfizer's stake sale in Sensodyne maker Haleon to Beijing joining the list of Chinese cities easing ...

On completion, Pfizer, the New York-based pharmaceuticals firm, will see its interest in Haleon fall to just over 16% from 22.6% currently. Bloomberg reported that the share sale price is likely to be ...

Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million ...

Goldman Sachs, JP Morgan, Morgan Stanley and UBS are global coordinators on the trade, with Barclays, Bank of America, BNP ...